Checkpoint Therapeutics - CKPT Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $22.60
  • Forecasted Upside: 807.63%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$2.49
▼ -0.09 (-3.49%)

This chart shows the closing price for CKPT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Checkpoint Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CKPT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CKPT

Analyst Price Target is $22.60
▲ +807.63% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Checkpoint Therapeutics in the last 3 months. The average price target is $22.60, with a high forecast of $47.00 and a low forecast of $4.00. The average price target represents a 807.63% upside from the last price of $2.49.

This chart shows the closing price for CKPT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 5 contributing investment analysts is to buy stock in Checkpoint Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/30/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/30/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/29/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/27/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/25/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/24/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/23/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/23/2024

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/16/2024HC WainwrightReiterated RatingBuy ➝ Buy$34.00 ➝ $34.00Low
6/24/2024HC WainwrightReiterated RatingBuy ➝ Buy$34.00 ➝ $34.00Low
5/16/2024HC WainwrightReiterated RatingBuy ➝ Buy$34.00Low
3/22/2024HC WainwrightReiterated RatingBuy ➝ Buy$34.00Low
12/20/2023B. RileyLower TargetBuy ➝ Buy$8.00 ➝ $4.00Low
12/19/2023HC WainwrightReiterated RatingBuy ➝ Buy$34.00Low
8/16/2023Lake Street CapitalLower TargetBuy ➝ Buy$16.00 ➝ $14.00Low
8/15/2023LADENBURG THALM/SH SHLower TargetBuy ➝ Buy$65.00 ➝ $47.00Low
8/15/2023Cantor FitzgeraldLower TargetOverweight ➝ Overweight$19.00 ➝ $14.00Low
8/4/2023HC WainwrightReiterated RatingBuy ➝ Buy$34.00Low
5/30/2023Lake Street CapitalLower Target$22.00 ➝ $16.00Low
5/17/2023LADENBURG THALM/SH SHLower Target$69.00 ➝ $65.00Low
5/16/2023Cantor FitzgeraldLower Target$54.00 ➝ $19.00Low
4/28/2023HC WainwrightLower Target$76.00 ➝ $34.00Low
4/4/2023Lake Street CapitalLower TargetBuy$32.00 ➝ $22.00Low
4/3/2023LADENBURG THALM/SH SHLower TargetBuy$96.00 ➝ $69.00Low
3/2/2023Lake Street CapitalLower Target$41.00 ➝ $32.00Low
3/2/2023HC WainwrightReiterated RatingBuy$76.00Low
12/23/2022HC WainwrightBoost TargetBuy$26.00 ➝ $76.00Low
12/19/2022B. RileyBoost TargetBuy$7.00 ➝ $15.00Low
7/14/2022B. RileyReiterated RatingBuy$70.00Low
1/26/2022LADENBURG THALM/SH SHBoost Target$200.00 ➝ $260.00Medium
1/26/2022Cantor FitzgeraldBoost Target$160.00 ➝ $200.00Medium
1/25/2022HC WainwrightBoost TargetBuy$170.00 ➝ $260.00High
6/8/2021B. RileyInitiated CoverageBuy$180.00High
2/1/2021Cantor FitzgeraldReiterated RatingOverweightHigh
1/19/2021Cantor FitzgeraldInitiated CoverageOverweight$160.00High
9/29/2020HC WainwrightBoost TargetBuy$150.00 ➝ $170.00High
8/6/2020HC WainwrightReiterated RatingBuy$150.00High
7/15/2020LADENBURG THALM/SH SHReiterated RatingBuy$200.00Medium
6/25/2020HC WainwrightReiterated RatingBuy$150.00High
3/12/2020HC WainwrightReiterated RatingBuy$150.00High
12/27/2019Lake Street CapitalReiterated RatingBuy$120.00 ➝ $80.00High
9/30/2019HC WainwrightReiterated RatingBuy$150.00Low
8/9/2019HC WainwrightReiterated RatingBuy$150.00Medium
(Data available from 7/23/2019 forward)

News Sentiment Rating

0.78 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 3 very negative mentions
12/26/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/25/2024
  • 0 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/24/2024
  • 2 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
3/25/2024
  • 2 very positive mentions
  • 29 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/24/2024
  • 2 very positive mentions
  • 28 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
5/24/2024
  • 1 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
6/23/2024
  • 3 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/23/2024

Current Sentiment

  • 3 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Checkpoint Therapeutics logo
Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It is developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.
Read More

Today's Range

Now: $2.49
Low: $2.45
High: $2.63

50 Day Range

MA: $2.05
Low: $1.56
High: $2.68

52 Week Range

Now: $2.49
Low: $1.30
High: $3.62

Volume

415,175 shs

Average Volume

471,242 shs

Market Capitalization

$88.87 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.25

Frequently Asked Questions

What sell-side analysts currently cover shares of Checkpoint Therapeutics?

The following sell-side analysts have issued reports on Checkpoint Therapeutics in the last year: B. Riley, Cantor Fitzgerald, HC Wainwright, LADENBURG THALM/SH SH, and Lake Street Capital.
View the latest analyst ratings for CKPT.

What is the current price target for Checkpoint Therapeutics?

5 Wall Street analysts have set twelve-month price targets for Checkpoint Therapeutics in the last year. Their average twelve-month price target is $22.60, suggesting a possible upside of 807.6%. LADENBURG THALM/SH SH has the highest price target set, predicting CKPT will reach $47.00 in the next twelve months. B. Riley has the lowest price target set, forecasting a price of $4.00 for Checkpoint Therapeutics in the next year.
View the latest price targets for CKPT.

What is the current consensus analyst rating for Checkpoint Therapeutics?

Checkpoint Therapeutics currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CKPT will outperform the market and that investors should add to their positions of Checkpoint Therapeutics.
View the latest ratings for CKPT.

What other companies compete with Checkpoint Therapeutics?

How do I contact Checkpoint Therapeutics' investor relations team?

Checkpoint Therapeutics' physical mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The company's listed phone number is (781) 652-4500 and its investor relations email address is [email protected]. The official website for Checkpoint Therapeutics is www.checkpointtx.com. Learn More about contacing Checkpoint Therapeutics investor relations.